312 completed, 68 unknown, 54 terminated, 38 recruiting. 518 Phase 2, 90 Phase 1, 63 Phase 3.
Follow Diabetes Complications: new trials by email Literature Review of Diabetes Complications trials Research Report on Diabetes Complications
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. Sotagliflozin initiation - Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM) | Phase 2 | Not yet recruiting | HealthPartners Institute | 80 | 2027-01-01 | 2026-10-23 |
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Not yet recruiting | University Medical Center Groningen | 36 | 2027-01-01 | 2026-10-20 |
| Perineural Botulinum Toxin Injection Versus Oral Duloxetine in Relief of Foot Pain in Painful Peripheral Diabetic Neuropathy Botulinum Toxin Type A, Duloxetine, Oral Placebo Tablet - Diabetic Peripheral Neuropathy, Painful Diabetic Neuropathy | Phase 2 | Not yet recruiting | Assiut University | 56 | 2026-11-01 | 2026-10-20 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes PAL-119, Placebo - Healthy Volunteers and Diabetes Participants | Phase 1 / Phase 2 | Not yet recruiting | Paulex Bio Inc. | 147 | 2026-11-01 | 2026-10-28 |
| Evaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Diabetic Foot Ulcers PRFM, Standard of Care (SoC) - Diabetic Foot Ulcer (DFU), Ulcer | Phase 1 / Phase 2 | Not yet recruiting | Tiger Biosciences, LLC. | 55 | 2026-09-01 | 2026-09-25 |
| Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus Topical anti-Staphylococcus bacteriophage therapy, Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy - Diabetic Foot, Staphylococcal Infections | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nīmes | 60 | 2026-09-01 | 2026-03-20 |
| The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer. L- carnitine - Diabetic Foot Ulcer, Diabetic Foot Ulcer (DFU) | Phase 2 | Recruiting | Ain Shams University | 50 | 2026-09-01 | 2026-08-17 |
| A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF - Diabetic Macular Edema (DME) | Phase 2 | Recruiting | BioAge Labs, Inc. | 180 | 2026-08-21 | 2026-10-27 |
| Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU Antimicrobial agent - Diabetic Foot Ulcers (DFUs) | Phase 2 | Recruiting | Lakewood-Amedex Inc | 24 | 2026-08-14 | 2026-09-02 |
| Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial Umbilical Cord Mesenchymal Stem Cells - Diabetic Nephropathy Type 2 | Phase 1 / Phase 2 | Recruiting | PT. Prodia Stem Cell Indonesia | 10 | 2026-07-01 | 2026-02-09 |
| Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care Standard of Care (SOC), SoC + Low dose CYWC628, SoC + High dose CYWC628 - Diabetic Foot Ulcer (DFU) | Phase 1 / Phase 2 | Recruiting | FibroBiologics | 120 | 2026-06-01 | 2026-08-26 |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Surabgene Lomparvovec, Sham, Topical Steroid - Diabetic Retinopathy | Phase 2 / Phase 3 | Recruiting | AbbVie | 576 | 2026-06-01 | 2026-10-29 |
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy SCD411 0.05mL (2mg) - Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 2 | Completed | Sam Chun Dang Pharm. Co. Ltd. | 33 | 2026-05-13 | 2026-06-08 |
| Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution - Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies | Phase 1 / Phase 2 | Recruiting | Florida A&M University | 20 | 2026-04-02 | 2026-04-29 |
| The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy DLBS1033, Placebo Comparator: Placebo + Standard Therapy - Diabetic Polyneuropathy, Peripheral Nervous System Diseases | Phase 2 / Phase 3 | Not yet recruiting | Universitas Sebelas Maret | 34 | 2026-03-01 | 2026-03-16 |
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) | Phase 2 | Completed | Qlaris Bio, Inc. | 9 | 2026-02-20 | 2026-11-02 |
| Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease ALN-ANG3, Evinacumab, Placebo - Diabetic Kidney Disease (DKD) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 195 | 2026-01-09 | 2026-10-27 |
| Mesenchymal Stem Cells for Chronic Kidney Diseases 0.9% sodium chloride, MSCs - Kidney Disease, Chronic, Diabetic Kidney Disease (DKD) | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 32 | 2026-01-01 | 2025-12-24 |
| Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling hypoglycemic treatment, Tangshen'an Granules, Ginkgo Leaf Tablets - Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Not yet recruiting | Hejiang Ye | 160 | 2026-01-01 | 2025-09-26 |
| Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes Arginine hydrochloride, Sodium Chloride 0.9% - Diabetes (DM), Diabetic Ketoacidosis | Phase 1 / Phase 2 | Recruiting | David K Carroll | 60 | 2025-12-19 | 2026-02-12 |
Showing 20 of 518. Sign in to see all of them.
Diabetic Nephropathies (140) · Diabetic Foot (131) · Diabetes Mellitus (126) · Diabetic Neuropathies (119) · Diabetic Retinopathy (99) · Diabetes Mellitus, Type 2 (52) · Renal Insufficiency, Chronic (27) · Diabetes Mellitus, Type 1 (25) · Neuralgia (24) · Pain (23) · Foot Ulcer (22) · Macular Edema (21) · Kidney Diseases (19) · Proteinuria (14)
Endocrine System Diseases (514) · Diabetes Mellitus (392) · Cardiovascular Diseases (246) · Vascular Diseases (241) · Diabetic Angiopathies (227) · Nutritional and Metabolic Diseases (188) · Metabolic Diseases (185) · Glucose Metabolism Disorders (180) · Urogenital Diseases (146) · Female Urogenital Diseases and Pregnancy Complications (144) · Female Urogenital Diseases (143) · Male Urogenital Diseases (143) · Urologic Diseases (139) · Pathological Conditions, Signs and Symptoms (138)
Standard of Care (24) · aflibercept (16) · Ranibizumab (14) · Saline Solution (11) · Bevacizumab (10) · Sodium Chloride (10) · Insulin Aspart (8) · Pregabalin (8) · salicylhydroxamic acid (7) · Atrasentan (6) · Triamcinolone Acetonide (6) · Insulin, Regular, Human (5) · dapagliflozin (5) · empagliflozin (5) · finerenone (5)
Pfizer (12) · University of Sao Paulo (11) · Ain Shams University (8) · Florida Atlantic University (8) · AstraZeneca (7) · Bayer (7) · Tanabe Pharma Corporation (7) · AbbVie (prior sponsor, Abbott) (6) · Novartis Pharmaceuticals (6) · Boehringer Ingelheim (5) · University of Colorado, Denver (5) · AbbVie (4) · Baylor College of Medicine (4) · Eli Lilly and Company (4) · GlaxoSmithKline (4)
United States (236) · Germany (48) · United Kingdom (44) · Denmark (31) · Poland (30) · Canada (29) · Spain (29) · Czechia (27) · Italy (27) · Australia (25) · China (21) · Hungary (21) · Israel (20) · Japan (20) · Mexico (19)
Betty Tuller, PhD (4) · Aziz Shaibani, MD (3) · Betty Tuller, Ph.D (3) · David Prior (3) · Petter Bjornstad, MD (3) · Ahmed Aly Massoud, PhD (2) · Angela Hansen (2) · Blai Coll, MD (2)
PMID 33107592, PMID 41805697, PMID 28756065, PMID 37916745, PMID 18619874, PMID 23986513, PMID 31583611, PMID 32301137, PMID 32974732, PMID 35587172, PMID 38537621, PMID 11238785, PMID 11304102, PMID 11565517, PMID 11565518, PMID 11832527, PMID 12684357, PMID 15273542, PMID 15380496, PMID 15504999, PMID 15632335, PMID 15834546, PMID 16120818, PMID 16188903, PMID 17237664, PMID 17342504, PMID 17353400, PMID 17392551, PMID 17508198, PMID 17698196, PMID 17765429, PMID 18185135, PMID 18403219, PMID 18430778, PMID 18435772, PMID 18525041, PMID 18701613, PMID 19208678, PMID 19268890, PMID 19420913, PMID 19454870, PMID 19808241, PMID 19954692, PMID 20150934, PMID 20212194, PMID 20212197, PMID 20693353, PMID 20700413, PMID 20876408, PMID 20923537
2018 (8), 2016 (7), 2019 (4), 2008 (2), 2009 (2), 2014 (2), 2015 (2), 2017 (2), 2023 (2), R21AT004490 (2), 1KL2RR025015-01 (1), 2004 (1), 2005 (1), I01CX000264 (1), OT2NS122680-01 (1)